Premium
Interleukin‐12 Gene Therapy Prevents Establishment of SCC VII Squamous Cell Carcinomas, Inhibits Tumor Growth, and Elicits Long‐term Antitumor Immunity in Syngeneic C3H Mice
Author(s) -
Myers Jeffrey N.,
MankSeymour Amy,
Zitvogel Laurence,
Storkus Walter,
Clarke Martha,
Johnson Candace S.,
Tahara Hideaki,
Lotze Michael T.
Publication year - 1998
Publication title -
the laryngoscope
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.181
H-Index - 148
eISSN - 1531-4995
pISSN - 0023-852X
DOI - 10.1097/00005537-199802000-00019
Subject(s) - genetic enhancement , cancer research , biology , cell , gene , cell culture , microbiology and biotechnology , immunology , biochemistry , genetics
Interleukin‐12 (IL‐12) is an immunostimulatory agent with very promising antitumor activity. Using a retroviral expression vector, the authors have successfully transduced the genes encoding the two subunits of murine IL‐12 to the squamous cell carcinoma cell line, SCC VII. Once IL‐12 gene transcription and protein production were successfully verified, IL‐12 expression was found to inhibit the establishment of SCC VII tumors in syngeneic C3H/HeJ mice inoculated with 1 × 10 6 SCC VII/IL‐12 viable tumor cells. Mice immunized in this manner and rechallenged with parent SCC VII were capable of rejecting tumor up to 40% of the time. Treatment of established SCC VII tumors with irradiated IL‐12‐producing tumors cells led to significant tumor regression in a high percentage of animals.